弥漫大B细胞淋巴瘤的预后影响因素研究进展
Research Progress on Prognostic Factors in Diffuse Large B-Cell Lymphoma
DOI: 10.12677/ACM.2024.141018, PDF,    科研立项经费支持
作者: 邵乐天：新疆医科大学，新疆 乌鲁木齐；李 燕*：新疆维吾尔自治区人民医院血液科，新疆 乌鲁木齐
关键词: 弥漫大B细胞淋巴瘤；预后；预后模型；Diffuse Large B Cell Lymphoma； Prognosis； Prognostic Model
摘要: 弥漫大Ｂ细胞淋巴瘤(Diffuse large B cell lymphoma, DLBCL)作为非霍奇金淋巴瘤常见的亚型，具有高度的异质性。目前，迫切需要建立精确的预后模型对DLBCL分层，以开发更加个体化的DLBCL治疗方案。当前广泛应用于临床的预后模型，主要是基于IPI的临床变量。随着病理学、实验室和分子生物学特征对DLBCL患者预后的意义不断加深，可以提高现有模型的分层和预后能力。探索一个最佳的预后模型是目前研究的热点。本文回顾了常见的三种预后模型，分析其存在的缺陷，并对新的临床参数和生物标志物的预后分层价值进行综述。
Abstract: Diffuse large B-cell lymphoma (Diffuse large B cell lymphoma, DLBCL), as a common subtype of non-Hodgkin’s lymphoma, is highly heterogeneous. At present, it is urgent to establish an accurate prognostic model to stratify DLBCL in order to develop a more individualized treatment plan for DLBCL. At present, the prognosis model which is widely used in clinic is mainly based on the clinical variables of IPI. With the increasing significance of pathological, laboratory and molecular biological characteristics in the prognosis of patients with DLBCL, the stratification and prognostic ability of existing models can be improved. To explore an optimal prognostic model is the focus of the current research. This paper reviews three common prognostic models, analyzes their defects, and reviews the prognostic stratification value of new clinical parameters and biomarkers.
文章引用：邵乐天, 李燕. 弥漫大B细胞淋巴瘤的预后影响因素研究进展[J]. 临床医学进展, 2024, 14(1): 126-130. https://doi.org/10.12677/ACM.2024.141018

参考文献

[1] Lenz, G. and Staudt, L.M. (2010) Aggressive Lymphomas. The New England Journal of Medicine, 362, 1417-1429. [Google Scholar] [CrossRef] 
[2] The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. The New England Journal of Medicine, 329, 987-994. [Google Scholar] [CrossRef] 
[3] Zhou, Z., Sehn, L.H., Rademaker, A.W., et al. (2014) An Enhanced International Prognostic Index (NCCN-IPI) for Patients with Diffuse Large B-Cell Lymphoma Treated in the Rituximab Era. Blood, 123, 837-842. [Google Scholar] [CrossRef] [PubMed]
[4] Sehn, L.H., Berry, B., Chhanabhai, M., et al. (2007) The Re-vised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 109, 1857-1861. [Google Scholar] [CrossRef] [PubMed]
[5] Tay, K., Tai, D., Tao, M., et al. (2011) Relevance of the Inter-national Prognostic Index in the Rituximab Era. Journal of Clinical Oncology, 29, e14-e15. [Google Scholar] [CrossRef] 
[6] Ruppert, A.S., Dixon, J.G., Salles, G., et al. (2020) International Prognostic Indices in Diffuse Large B-Cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI. Blood, 135, 2041-2048. [Google Scholar] [CrossRef] [PubMed]
[7] Warnnissorn, N., Kanitsap, N., Niparuck, P., et al. (2022) External Validation and Comparison of IPI, R-IPI, and NCCN-IPI in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP to Predict 2-Year Progression-Free Survival. Hematology, 27, 1237-1245. [Google Scholar] [CrossRef] [PubMed]
[8] Shi, X., Liu, X., Li, X., et al. (2021) Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study. Frontiers in Oncology, 11, Article ID: 754964. [Google Scholar] [CrossRef] [PubMed]
[9] Schmitz, R., Wright, G.W., Huang, D.W., et al. (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 378, 1396-1407. [Google Scholar] [CrossRef] 
[10] Chapuy, B., Stewart, C., Dunford, A.J., et al. (2018) Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes. Na-ture Medicine, 24, 679-690. [Google Scholar] [CrossRef] [PubMed]
[11] Lacy, S.E., Barrans, S.L., Beer, P.A., et al. (2020) Targeted Se-quencing in DLBCL, Molecular Subtypes, and Outcomes: A Haematological Malignancy Research Network Report. Blood, 135, 1759-1771. [Google Scholar] [CrossRef] [PubMed]
[12] Wright, G.W., Huang, D.W., Phelan, J.D., et al. (2020) A Proba-bilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Can-cer Cell, 37, 551-568. [Google Scholar] [CrossRef] [PubMed]
[13] Ma, J., Yan, Z., Zhang, J., et al. (2020) A Genetic Predictive Mod-el for Precision Treatment of Diffuse Large B-Cell Lymphoma with Early Progression. Biomarker Research, 8, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[14] Song, J.Y., Perry, A.M., Herrera, A.F., et al. (2018) New Ge-nomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 132, 346. [Google Scholar] [CrossRef] 
[15] Kline, J., Godfrey, J. and Ansell, S.M. (2020) The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma. Blood, 135, 523-533. [Google Scholar] [CrossRef] [PubMed]
[16] Ciavarella, S., Vegliante, M.C., Fabbri, M., et al. (2018) Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue. Annals of Oncology, 29, 2363-2370. [Google Scholar] [CrossRef] [PubMed]
[17] Ghorab, D.S., Helaly, A.M., El Mahdi, M.S., et al. (2022) Prognostic Role of Tumor Microenvironment in DLBCL and Relation to Patients’ Clinical Outcome: A Clinical and Immunohisto-chemical Study. Analytical Cellular Pathology, 2022, Article ID: 9993496. [Google Scholar] [CrossRef] [PubMed]
[18] Solimando, A.G., Annese, T., Tamma, R., et al. (2020) New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers, 12, 1869. [Google Scholar] [CrossRef] [PubMed]
[19] Kotlov, N., Bagaev, A., Revuelta, M.V., et al. (2021) Clinical and Biological Subtypes of B-Cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discovery, 11, 1468-1489. [Google Scholar] [CrossRef] 

为你推荐